Watch HLSQ. Know when insiders buy.
One email the day a filing lands. Free.
HLSQ
BiomX Inc.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$45.5MNET DEBT $10.8M52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $332K | — | 29.2% | −$5.4M | −$3.8M | — | 0.37 | −$1.2M | — | — | Aug 19 |
| Q1 2026 · Mar 31 | — | — | — | −$1.3M | −$19.1M | — | 7.38 | −$5.4M | — | — | May 20 |
| Q4 2025 · Dec 31derived | — | — | — | −$17.7M | −$13.3M | — | 21.39 | −$4.4M | $0 | −$4.4M | Feb 19 |
| Q3 2025 · Sep 30 | — | — | — | −$8.5M | −$9.2M | −195.1% | 0.29 | −$7.2M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$7.4M | −$6M | −235.0% | 3.66 | −$6.1M | — | — | Aug 19 |
| Q1 2025 · Mar 31 | — | — | — | −$7.8M | −$7.7M | — | 6.27 | −$8.7M | — | — | May 20 |
| Q4 2024 · Dec 31derived | — | — | — | −$16.7M | −$14.5M | — | 55.86 | −$6.3M | $11K | −$6.3M | Feb 19 |
| Q3 2024 · Sep 30 | — | — | — | −$11.3M | $9.6M | — | -0.31 | −$8.1M | $10K | −$8.1M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$9.7M | $4.5M | — | 0.69 | −$11.2M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$6.8M | −$17.3M | — | 2.78 | −$11.4M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$5.3M | −$5.5M | — | 0.81 | −$6.2M | $7K | −$6.2M | Mar 25 |
| Q3 2023 · Sep 30 | — | — | — | −$7.8M | −$7.9M | — | 1.30 | −$5.9M | $32K | −$6M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$41.5M | −$36.2M | — | 22.19 | −$26.4M | $2K | −$26.4M | — | — |
| FY2024 · to Dec 31 | — | — | −$44.5M | −$17.7M | — | 58.31 | −$37M | $30K | −$37M | — | — |
| FY2023 · to Dec 31 | — | — | −$25.3M | −$26.2M | — | 5.10 | −$21.3M | $50K | −$21.3M | — | — |
| FY2022 · to Dec 31 | — | — | −$27.2M | −$28.3M | — | 0.95 | −$29.1M | $112K | −$29.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$35.5M | −$36.2M | — | 1.39 | −$27.6M | $3.7M | −$31.3M | — | — |
| FY2020 · to Dec 31 | — | — | −$30.3M | −$30.1M | — | 1.30 | −$24.4M | $1M | −$25.5M | — | — |
Every number comes from BiomX Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.